Psoriatic Arthritis

Patients with PsA who achieved low disease activity had a 76% - 79% improvement in the Global Assessment and Pain composite.

A study found patients with PsA have greater healthcare costs for herpes zoster than patients without PsA.

Administrative claims database analysis revealed a lower AMD incidence in patients treated with JAK inhibitor therapy versus non–JAK-based immunotherapy.

Casey Schlacher discusses the FDA approval of the new weight-based oral solution, RINVOQ LQ (upadacitinib), for treating pediatric patients with arthritis, highlighting its importance for improving patient outcomes and quality of life.

Test your knowledge of active oligoarthritis treatment recommendations from the 2021 ACR guideline on JIA with this quiz.

An observational study found patients with chronic inflammatory diseases who smoke may respond less to biologics than non-smokers.

Gerd Burmester, MD, discusses the favorable long-term safety data of upadacitinib treatment across rheumatic diseases.

A survey shows females with PsA have a greater disease burden than males with PsA.

A study found patients with psoriasis and psoriatic arthritis had a polyneuropathy relative risk of 22.09. However, an analysis revealed the neuropathy risk was not significant.

Older children (aged >5 years) with JIA exhibited a 40% to 45% higher point prevalence of active disease at month 12 when compared with younger patients.

Discontinuation was less likely in the prospective Patient Support Program (PSP) group compared with the retrospective non-PSP group.

A study describes the structure and function differences of the Achilles tendon for PsA patients who self-report pain and those who don’t.

Patients with psoriasis on biological agents might have a lower PsA risk than those on methotrexate, but patients on topical therapy have an even lower risk, a study found.

Among patients with PsA, men tend to present more peripheral joint movement, and women tend to exhibit more axial involvement, a new study found.

Adults with active PsA treated with guselkumab exhibited durable achievement of study endpoints associated with disease control, irrespective of baseline characteristics.

The approval was based on previous data from well-controlled RA studies coupled with findings from a multinational, dose-finding study of pediatric patients with pJIA.

cfPWV values were significantly higher in patients with PsA compared with controls, even after adjusting for confounders.

The approvals were based on data from well-controlled studies of the drug in adult patients with PsA and RA.

After initiating treatment with ixekizumab, tender and swollen joint counts, pain, fatigue, and body surface area affected by psoriasis were significantly improved.

Combining algorithms SCORE2 and QRISK3 created the best predictive model to predict the cardiovascular risk for patients with PsA.

These data highlight the role of the National Health Service, though the relationship between socio-economic background and health outcomes remains complex.

An analysis of more than 1800 adults with psoriatic arthritis found more than 20% of patients report widespread pain, with 10% meeting fibromyalgia criteria.

An IMID diagnosis or use of immunomodulatory medications were not shown to be a significant risk factor of severe COVID-19 outcomes.

Those with coexisting PsA and atopic dermatitis needed to switch to a higher number of biologics to achieve disease control.

Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.

Patients often rely on opioids a year before and a year after a diagnosis of ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis.

Using a cut-off value of 7.1 kPA for liver stiffness, results of the transient elastography yielded 100% sensitivity and 68% specificity among this patient population.

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.

A pooled analysis revealed a loading-dose regimen, especially for patients receiving secukinumab 150 mg for PsA, increases the odds of disease improvement.